MS biologics comparison

Neurology

Compare disease-modifying therapies (DMTs) for multiple sclerosis. Options range from platform therapies to high-efficacy B-cell depleting agents. Choice depends on disease activity, safety profile, route preference, and insurance coverage.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
OcrevusGenentech/RocheIV infusionEvery 6 monthsOnly FDA-approved treatment for primary progressive MS; high-efficacy anti-CD20
KesimptaNovartisSC injection (at home)MonthlySelf-administered anti-CD20; no infusion center required
BriumviTG TherapeuticsIV infusionEvery 6 monthsAnti-CD20; potentially lower cost than Ocrevus
TysabriBiogenIV infusionEvery 4 weeksHigh efficacy; requires JCV monitoring (PML risk); REMS program
GilenyaNovartisOral (capsule)DailyFirst oral MS therapy; S1P receptor modulator; requires first-dose monitoring
TecfideraBiogenOral (capsule)Twice dailyOral fumarate; generics now available (dimethyl fumarate)
VumerityBiogenOral (capsule)Twice dailyNext-gen fumarate; potentially fewer GI side effects than Tecfidera
MavencladMerck KGaAOral (tablet)2 treatment courses over 2 years, then off therapyShort-course therapy with long-lasting effect; no daily medication
RebifMerck KGaASC injection3 times weeklyInterferon beta-1a; platform therapy; long track record

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.